(Total Views: 327)
Posted On: 09/08/2021 9:58:15 AM
Post# of 36564
Welcome to the forum. Another aspect:
AE37 is unique in stimulating CD4 T cells as well as CD8 for a far longer lasting effect. E75 and GP2 ctl CD8 only.
The ten year data is impressive for AE37. I was hoping to see Dr Mittendorf present that at ASCO. The did for the extreme subset data for GP2 which propelled that company’s stock. Generex owes funding to the HM Jackson Foundation so I’m curious if that effects data Mittendorf presents. Hopefully that’s not the case.
AE37 is unique in stimulating CD4 T cells as well as CD8 for a far longer lasting effect. E75 and GP2 ctl CD8 only.
The ten year data is impressive for AE37. I was hoping to see Dr Mittendorf present that at ASCO. The did for the extreme subset data for GP2 which propelled that company’s stock. Generex owes funding to the HM Jackson Foundation so I’m curious if that effects data Mittendorf presents. Hopefully that’s not the case.
(5)
(0)
